Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

• Citi's 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m. ET
• Morgan Stanley 21st Annual Global Healthcare Conference: Wednesday, September 13 12:55-1:25 p.m. ET

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.

You May Also Be Interested In

• LGA Garage Door Service Strengthens Texas Operations With Expanded Inventory and In-House Service Capacity
• Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
• Former Under Secretary of Defense Michèle Flournoy and Former USSOCOM Commander Admiral Eric T. Olson Join Spirit of America Board of Directors